Myomo, Inc. (NYSEAMERICAN:MYO – Get Free Report) insider Harry Kovelman sold 11,536 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $1.02, for a total value of $11,766.72. Following the completion of the sale, the insider owned 108,618 shares in the company, valued at approximately $110,790.36. This represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Myomo Price Performance
Shares of MYO stock traded up $0.09 during trading hours on Thursday, hitting $1.09. The company had a trading volume of 725,122 shares, compared to its average volume of 476,823. Myomo, Inc. has a 12 month low of $0.61 and a 12 month high of $3.14. The firm has a market capitalization of $42.12 million, a price-to-earnings ratio of -3.03 and a beta of 1.39. The firm’s fifty day moving average is $0.81 and its 200 day moving average is $0.85. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.36 and a current ratio of 2.73.
Hedge Funds Weigh In On Myomo
Institutional investors have recently modified their holdings of the stock. Lazard Asset Management LLC bought a new position in shares of Myomo in the second quarter worth about $98,000. Engineers Gate Manager LP raised its stake in shares of Myomo by 62.8% in the second quarter. Engineers Gate Manager LP now owns 30,097 shares of the company’s stock worth $65,000 after acquiring an additional 11,614 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Myomo in the second quarter worth about $38,000. New York State Common Retirement Fund acquired a new position in Myomo during the 2nd quarter worth $97,000. Finally, XTX Topco Ltd acquired a new position in Myomo during the 2nd quarter worth $134,000. 44.99% of the stock is owned by institutional investors.
Analyst Ratings Changes
Check Out Our Latest Stock Report on MYO
About Myomo
Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.
Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.
Featured Stories
- Five stocks we like better than Myomo
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.
